Search

Your search keyword '"Vehreschild, J. Janne"' showing total 24 results
Start Over Author "Vehreschild, J. Janne"
24 results on '"Vehreschild, J. Janne"'

1. Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron—results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)

Author

Hopff, Sina M., Appel, Katharina S., Miljukov, Olga, Schneider, Johannes, Addo, Marylyn M., Bals, Robert, Bercker, Sven, Blaschke, Sabine, Bröhl, Isabel, Büchner, Nikolaus, Dashti, Hiwa, Erber, Johanna, Friedrichs, Anette, Geisler, Ramsia, Göpel, Siri, Hagen, Marina, Hanses, Frank, Jensen, Björn-Erik Ole, Keul, Maria, Krawczyk, Adalbert, Lorenz-Depiereux, Bettina, Meybohm, Patrick, Milovanovic, Milena, Mitrov, Lazar, Nürnberger, Carolin, Obst, Wilfried, Römmele, Christoph, Schäfer, Christian, Scheer, Christian, Scherer, Margarete, Schmidt, Julia, Seibel, Kristina, Sikdar, Shimita, Tebbe, Johannes Josef, Tepasse, Phil-Robin, Thelen, Philipp, Vehreschild, Maria J. G. T., Weismantel, Christina, and Vehreschild, J. Janne

Published
2024
Full Text
View/download PDF

2. Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study

Author

Hopff, Sina M., Wingen-Heimann, Sebastian M., Classen, Annika Y., Blau, Igor-Wolfgang, Bug, Gesine, Hebermehl, Corinna, Kraus, Sabrina, Penack, Olaf, Rettig, Andrés R., Schmitt, Timo, Steinbrunn, Torsten, Teschner, Daniel, Vehreschild, Maria J.G.T., Wehr, Claudia, and Vehreschild, J. Janne

Published
2024
Full Text
View/download PDF

3. Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany

Author

Tilch, Katharina, Hopff, Sina M., Appel, Katharina, Kraus, Monika, Lorenz-Depiereux, Bettina, Pilgram, Lisa, Anton, Gabi, Berger, Sarah, Geisler, Ramsia, Haas, Kirsten, Illig, Thomas, Krefting, Dagmar, Lorbeer, Roberto, Mitrov, Lazar, Muenchhoff, Maximilian, Nauck, Matthias, Pley, Christina, Reese, Jens-Peter, Rieg, Siegbert, Scherer, Margarete, Stecher, Melanie, Stellbrink, Christoph, Valentin, Heike, Winter, Christof, Witzenrath, Martin, and Vehreschild, J. Janne

Published
2023
Full Text
View/download PDF

4. Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study

Author

Pilgram, Lisa, Appel, Katharina S., Ruethrich, Maria M., Koll, Carolin E. M., Vehreschild, Maria J. G. T., de Miranda, Susana M. Nunes, Hower, Martin, Hellwig, Kerstin, Hanses, Frank, Wille, Kai, Haselberger, Martina, Spinner, Christoph D., Vom Dahl, Juergen, Hertenstein, Bernd, Westhoff, Timm, Vehreschild, J. Janne, Jensen, Björn-Erik Ole, and Stecher, Melanie

Published
2023
Full Text
View/download PDF

5. Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV- 2 variants delta and omicron - results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)

Author

Hopff, Sina M., primary, Appel, Katharina S., additional, Miljukov, Olga, additional, Schneider, Johannes, additional, Addo, Marylyn M., additional, Bals, Robert, additional, Bercker, Sven, additional, Blaschke, Sabine, additional, Bröhl, Isabel, additional, Büchner, Nikolaus, additional, Dashti, Hiwa, additional, Erber, Johanna, additional, Friedrichs, Anette, additional, Geisler, Ramsia, additional, Göpel, Siri, additional, Hagen, Marina, additional, Hanses, Frank, additional, Jensen, Björn-Erik Ole, additional, Keul, Maria, additional, Krawczyk, Adalbert, additional, Lorenz-Depiereux, Bettina, additional, Meybohm, Patrick, additional, Milovanovic, Milena, additional, Mitrov, Lazar, additional, Nürnberger, Carolin, additional, Obst, Wilfried, additional, Römmele, Christoph, additional, Schäfer, Christian, additional, Scheer, Christian, additional, Scherer, Margarete, additional, Schmidt, Julia, additional, Seibel, Kristina, additional, Sikdar, Shimita, additional, Tebbe, Johannes Josef, additional, Tepasse, Phil-Robin, additional, Thelen, Philipp, additional, Vehreschild, Maria J.G.T., additional, Weismantel, Christina, additional, and Vehreschild, J. Janne, additional

Published
2024
Full Text
View/download PDF

6. A Systematic Review of Predictor Composition, Outcomes, Risk of Bias, and Validation of COVID-19 Prognostic Scores.

Author

Appel, Katharina S, Geisler, Ramsia, Maier, Daniel, Miljukov, Olga, Hopff, Sina M, and Vehreschild, J Janne

Subjects
RISK assessment, PREDICTION models, RESEARCH funding, EVALUATION of medical care, DESCRIPTIVE statistics, SEVERITY of illness index, SYSTEMATIC reviews, MEDLINE, SOCIODEMOGRAPHIC factors, COVID-19
Abstract

Background Numerous prognostic scores have been published to support risk stratification for patients with coronavirus disease 2019 (COVID-19). Methods We performed a systematic review to identify the scores for confirmed or clinically assumed COVID-19 cases. An in-depth assessment and risk of bias (ROB) analysis (Prediction model Risk Of Bias ASsessment Tool [PROBAST]) was conducted for scores fulfilling predefined criteria ([I] area under the curve [AUC)] ≥ 0.75; [II] a separate validation cohort present; [III] training data from a multicenter setting [≥2 centers]; [IV] point-scale scoring system). Results Out of 1522 studies extracted from MEDLINE/Web of Science (20/02/2023), we identified 242 scores for COVID-19 outcome prognosis (mortality 109, severity 116, hospitalization 14, long-term sequelae 3). Most scores were developed using retrospective (75.2%) or single-center (57.1%) cohorts. Predictor analysis revealed the primary use of laboratory data and sociodemographic information in mortality and severity scores. Forty-nine scores were included in the in-depth analysis. The results indicated heterogeneous quality and predictor selection, with only five scores featuring low ROB. Among those, based on the number and heterogeneity of validation studies, only the 4C Mortality Score can be recommended for clinical application so far. Conclusions The application and translation of most existing COVID scores appear unreliable. Guided development and predictor selection would have improved the generalizability of the scores and may enhance pandemic preparedness in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Ethical and coordinative challenges setting up a national cohort study during the COVID-19 pandemic in Germany

Author

Tilch, Katharina, primary, Hopff, Sina M., additional, Appel, Katharina, additional, Kraus, Monika, additional, Lorenz-Depiereux, Bettina, additional, Pilgram, Lisa, additional, Anton, Gabi, additional, Berger, Sarah, additional, Geisler, Ramsia, additional, Haas, Kirsten, additional, Illig, Thomas, additional, Krefting, Dagmar, additional, Lorbeer, Roberto, additional, Mitrov, Lazar, additional, Muenchhoff, Maximilian, additional, Nauck, Matthias, additional, Pley, Christina, additional, Reese, Jens-Peter, additional, Rieg, Siegbert, additional, Scherer, Margarete, additional, Stecher, Melanie, additional, Stellbrink, Christoph, additional, Valentin, Heike, additional, Winter, Christof, additional, Witzenrath, Martin, additional, and Vehreschild, J. Janne, additional

Published
2023
Full Text
View/download PDF

8. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Author

Marty, Francisco M, Ostrosky-Zeichner, Luis, Cornely, Oliver A, Mullane, Kathleen M, Perfect, John R, Thompson, George R, III, Alangaden, George J, Brown, Janice M, Fredricks, David N, Heinz, Werner J, Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A, Melinkeri, Sameer R, Oren, Ilana, Pappas, Peter G, Ráčil, Zdeněk, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J Janne, Young, Jo-Anne H, Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S, Engelhardt, Marc, Kaufhold, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M, Zeiher, Bernhardt, and Vehreschild, Maria J G T

Published
2016
Full Text
View/download PDF

10. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Author

Salmanton-García, Jon, Seidel, Danila, Koehler, Philipp, Mellinghoff, Sibylle, Herbrecht, Raoul, Klimko, Nikolai, Ráčil, Zdeněk, Falces-Romero, Iker, Ingram, Paul, Benítez-Peñuela, Miguel-Ángel, Rodríguez, José Yesid, Desoubeaux, Guillaume, Barać, Aleksandra, García-Vidal, Carolina, Hoenigl, Martin, Mehta, Sanjay, Cheng, Matthew, Klyasova, Galina, Heinz, Werner, Iqbal, Nousheen, Krause, Robert, Ostermann, Helmut, Penack, Olaf, Schalk, Enrico, Sheppard, Donald, Willinger, Birgit, Wisplinghoff, Hilmar, Vehreschild, J Janne, Cornely, Oliver, Vehreschild, Maria, Khedr, Reham Abdelaziz, Arencibia-Núñez, Alberto, Avilés-Robles, Martha, Banke, Ingo, Basher, Ariful, Benachinamardi, Keertilaxmi, Bertz, Harmut, Chakrabarti, Arunaloke, Drgona, Lubos, García-Martínez, Jesús, García-Rodríguez, Julio, Gräber, Sandra, Härter, Georg, Klein, Michael, Kouba, Michal, Lee, Dong-Gun, Le Govic, Yohann, Leo, Fabian, Maertens, Johan, Maschmeyer, Georg, Meintker, Lisa, Mo, Xiao-Dong, Müller, Lena-Katharina, Müller, Nicolas, Nel, Jeremy Stephen, Novák, Jan, Patel, Atul, Pfäfflin, Frieder, Pozo-Laderas, Juan-Carlos, Puerta-Alcalde, Pedro, Rodríguez-Guardado, Azucena, Schroers, Roland, Shekar, Vandana, Shenoi, Susan, Silling, Gerda, Vinh, Donald, Waizel-Haiat, Salomón, Yee Yee, Mandy Yap, Prakash, Peralam Yegneswaran, Žák, Pavel, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Service d'Hématologie, CHU Strasbourg, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medicine, Medical University Graz, Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Department of Haematology and Oncology, Medical Clinic III, University Hospital Munich—Großhadern, Ludwig Maximilian University, Klinik für Hämatologie und Onkologie, Charité, Campus Benjamin Franklin, Department of Haematology/Oncology, Magdeburg University Hospital, McGill University = Université McGill [Montréal, Canada], Medizinische Universität Wien = Medical University of Vienna, University Hospital of Cologne [Cologne], Postgraduate Institute of Medical Education and Research, Laboratoire de psychologie cognitive (LPC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Anofel Cryptosporidium National Network, Department of Hematology, University Hospital Gasthuisberg, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Real Expression Artificial Life (IRIT-REVA), Institut de recherche en informatique de Toulouse (IRIT), Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, Medizinische Klinik A des Universitätsklinikums Münster, Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Hospital Gasthuisberg [Leuven], Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, 0301 basic medicine, Posaconazole, Antifungal Agents, [SDV]Life Sciences [q-bio], Gastroenterology, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Amphotericin B, Pharmacology (medical), Prospective Studies, Registries, 030212 general & internal medicine, Child, Prospective cohort study, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, ComputingMilieux_MISCELLANEOUS, Antiinfective agent, Standard treatment, Middle Aged, 3. Good health, Infectious Diseases, Tolerability, Child, Preschool, Mucorales, Female, medicine.drug, Adult, Microbiology (medical), medicine.medical_specialty, Adolescent, Drug Compounding, Matched-Pair Analysis, 030106 microbiology, Young Adult, 03 medical and health sciences, Pharmacokinetics, Internal medicine, parasitic diseases, medicine, Humans, Mucormycosis, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [INFO]Computer Science [cs], Aged, Pharmacology, business.industry, Infant, Newborn, Infant, Triazoles, medicine.disease, business, MESH: amphotericin b, antifungal agents, cancer, kidney failure, mucormycosis, surgical procedures, operative, suspensions, mortality, posaconazole, Invasive Fungal Infections
Abstract

Background First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Conclusions Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Published
2019

12. FungiScope (TM) - Global Emerging Fungal Infection Registry

Author

Seidel, Danila, Graeff, Luisa A. Duran, Vehreschild, Maria J. G. T., Wisplinghoff, Hilmar, Ziegler, Maren, Vehreschild, J. Janne, Liss, Blasius, Hamprecht, Axel, Koehler, Philipp, Racil, Zdenek, Klimko, Nikolay, Sheppard, Donald C., Herbrecht, Raoul, Chowdhary, Anuradha, Cornely, Oliver A., Seidel, Danila, Graeff, Luisa A. Duran, Vehreschild, Maria J. G. T., Wisplinghoff, Hilmar, Ziegler, Maren, Vehreschild, J. Janne, Liss, Blasius, Hamprecht, Axel, Koehler, Philipp, Racil, Zdenek, Klimko, Nikolay, Sheppard, Donald C., Herbrecht, Raoul, Chowdhary, Anuradha, and Cornely, Oliver A.

Abstract

Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope (TM) is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope (TM) was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope (TM) have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope (TM) registry.

Published
2017

13. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Author

Marty, Francisco M., Ostrosky-Zeichner, Luis, Cornely, Oliver A., Mullane, Kathleen M., Perfect, John R., Thompson, George R., III, Alangaden, George J., Brown, Janice M., Fredricks, David N., Heinz, Werner J., Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A., Melinkeri, Sameer R., Oren, Ilana, Pappas, Peter G., Racil, Zdenek, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J. Janne, Young, Jo-Anne H., Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S., Engelhardt, Marc, Kaufh, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M., Zeiher, Bernhardt, Vehreschild, Maria J. G. T., Marty, Francisco M., Ostrosky-Zeichner, Luis, Cornely, Oliver A., Mullane, Kathleen M., Perfect, John R., Thompson, George R., III, Alangaden, George J., Brown, Janice M., Fredricks, David N., Heinz, Werner J., Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A., Melinkeri, Sameer R., Oren, Ilana, Pappas, Peter G., Racil, Zdenek, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J. Janne, Young, Jo-Anne H., Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S., Engelhardt, Marc, Kaufh, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M., Zeiher, Bernhardt, and Vehreschild, Maria J. G. T.

Abstract

Background Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis. Methods In a single-arm open-label trial (VITAL study), adult patients (>= 18 years) with invasive fungal disease caused by rare fungi, including mucormycosis, were recruited from 34 centres worldwide. Patients were given isavuconazole 200 mg (as its intravenous or oral water-soluble prodrug, isavuconazonium sulfate) three times daily for six doses, followed by 200 mg/day until invasive fungal disease resolution, failure, or for 180 days or more. The primary endpoint was independent data review committee-determined overall response-ie, complete or partial response (treatment success) or stable or progressive disease (treatment failure)-according to prespecified criteria. Mucormycosis cases treated with isavuconazole as primary treatment were matched with controls from the FungiScope Registry, recruited from 17 centres worldwide, who received primary amphotericin B-based treatment, and were analysed for day-42 all-cause mortality. VITAL is registered with ClinicalTrials.gov, number NCT00634049. FungiScope is registered with ClinicalTrials. gov, number NCT01731353. Findings Within the VITAL study, from April 22, 2008, to June 21, 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 days (IQR 19-179, range 2-882). By day 42, four patients (11%) had a partial response, 16 (43%) had stable invasive fungal disease, one (3%) had invasive fungal disease progression, three (8%) had missing assessments, and 13 (35%) had died. 35 patients (95%) had adverse events (28 [76%] serious). Day-42 crude all-cause mortality in seven (33%) of 21 primary-treatment isavuconazole cases was sim

Published
2016

14. The VITAL study: case control studies are hypothesis-generating Reply

Author

Cornely, Oliver A., Maher, Rochelle M., Marty, Francisco M., Lee, Misun, Vehreschild, J. Janne, Vehreschild, Maria J. G. T., Cornely, Oliver A., Maher, Rochelle M., Marty, Francisco M., Lee, Misun, Vehreschild, J. Janne, and Vehreschild, Maria J. G. T.

Published
2016

15. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis

Author

Biehl, Lena M., Vehreschild, J. Janne, Liss, Blasius, Franke, Bernd, Markiefka, Birgid, Persigehl, Thorsten, Buecker, Vanessa, Wisplinghoff, Hilmar, Scheid, Christof, Cornely, Oliver A., Vehreschild, Maria J. G. T., Biehl, Lena M., Vehreschild, J. Janne, Liss, Blasius, Franke, Bernd, Markiefka, Birgid, Persigehl, Thorsten, Buecker, Vanessa, Wisplinghoff, Hilmar, Scheid, Christof, Cornely, Oliver A., and Vehreschild, Maria J. G. T.

Abstract

Antifungal prophylaxis is recommended for haematological patients at high risk of invasive fungal infections (IFIs). Incidence, optimal therapeutic management and outcome of breakthrough IFIs (bIFIs) are largely unknown. To assess bIFI incidence, treatment and outcomes, data on patients undergoing AML remission-induction and consolidation chemotherapy and from allogeneic HSCT recipients on antifungal prophylaxis with itraconazole, micafungin or posaconazole were extracted from the Cologne Cohort of Neutropenic Patients (CoCoNut). bIFIs were classified according to revised EORTC/MSG criteria. From January 2004 to April 2013, 250 AML patients with 329 hospitalizations and 409 HSCT patients with 496 hospitalizations were identified. In AML patients, there were 16 (6.4%) proven or probable bIFIs and 44 (17.6%) possible bIFIs. In HSCT patients, there were 14 (3.4%) proven or probable bIFIs and 37 (9.0%) possible bIFIs. Proven cases included five candidaemias, two mucormycoses, three aspergilloses and one fusariosis. The most frequent choice for bIFI treatment was liposomal amphotericin B in AML patients (21/60; 35.0%) and continuation of posaconazole prophylaxis in HSCT patients (16/51; 31.4%). In HSCT recipients, survival on day 365 was significantly lower in bIFI patients (AML, 63.3% versus 70.0%; P=0.297; HSCT, 49.0% versus 66.8%; P=0.012). Comparison of continuation of prophylaxis versus switch of antifungal class as first-line treatment showed no significant difference regarding response to treatment and survival. Rates of bIFIs observed in our population were comparable to previous data. There was no clear shift towards rare species, as previously reported. A high variety of treatment approaches was observed.

Published
2016

17. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis

Author

Biehl, Lena M., primary, Vehreschild, J. Janne, additional, Liss, Blasius, additional, Franke, Bernd, additional, Markiefka, Birgid, additional, Persigehl, Thorsten, additional, Bücker, Vanessa, additional, Wisplinghoff, Hilmar, additional, Scheid, Christof, additional, Cornely, Oliver A., additional, and Vehreschild, Maria J. G. T., additional

Published
2016
Full Text
View/download PDF

19. PTX3 Deficiency and Aspergillosis

Author

Vehreschild, J. Janne, Vehreschild, Maria J. G. T., Cornely, Oliver A., Vehreschild, J. Janne, Vehreschild, Maria J. G. T., and Cornely, Oliver A.

Published
2014

20. Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope (TM)): Case Matched Analysis

Author

Vehreschild, Maria J. G. T., Vehreschild, J. Janne, Marty, Francisco M., Perfect, John R., Ostrosky-Zeichner, Luis, Rahav, Galia, Zeiher, Bernhardt, Lee, Misun, Maher, Rochelle, Lovell, Clint, Engelhardt, Marc, Cornely, Oliver A., Vehreschild, Maria J. G. T., Vehreschild, J. Janne, Marty, Francisco M., Perfect, John R., Ostrosky-Zeichner, Luis, Rahav, Galia, Zeiher, Bernhardt, Lee, Misun, Maher, Rochelle, Lovell, Clint, Engelhardt, Marc, and Cornely, Oliver A.

Published
2014

21. Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope™): Case Matched Analysis

Author

Vehreschild, Maria J.G.T., primary, Vehreschild, J. Janne, additional, Marty, Francisco M, additional, Perfect, John R, additional, Ostrosky-Zeichner, Luis, additional, Rahav, Galia, additional, Zeiher, Bernhardt, additional, Lee, Misun, additional, Maher, Rochelle, additional, Lovell, Clint, additional, Engelhardt, Marc, additional, and Cornely, Oliver A, additional

Published
2014
Full Text
View/download PDF

22. FungiScope™-Global Emerging Fungal Infection Registry.

Author

Seidel, Danila, Durán Graeff, Luisa A., Vehreschild, Maria J. G. T., Wisplinghoff, Hilmar, Ziegler, Maren, Vehreschild, J Janne, Liss, Blasius, Hamprecht, Axel, Köhler, Philipp, Racil, Zdenek, Klimko, Nikolay, Sheppard, Donald C., Herbrecht, Raoul, Chowdhary, Anuradha, Cornely, Oliver A., and FungiScope Group

Subjects
MYCOSES, PHYSICIANS, DRUGS, IMMUNOCOMPROMISED patients, EPIDEMIOLOGY
Abstract

Rare invasive fungal diseases ( IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope™ is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope™ was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope™ have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope™ registry. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

24. FungiScope ™ -Global Emerging Fungal Infection Registry.

Author

Seidel D, Durán Graeff LA, Vehreschild MJGT, Wisplinghoff H, Ziegler M, Vehreschild JJ, Liss B, Hamprecht A, Köhler P, Racil Z, Klimko N, Sheppard DC, Herbrecht R, Chowdhary A, Cornely OA, and FungiScope Group

Subjects
Humans, Immunocompromised Host, Invasive Fungal Infections, Quality Control, Communicable Diseases, Emerging, Global Health, Mycoses, Rare Diseases, Registries standards
Abstract

Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope ™ is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope ™ was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope ™ have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope ™ registry., (© 2017 Blackwell Verlag GmbH.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results